Fountain of Youth for the Eye? FDA Greenlights First-Ever Rejuvenation Trial

BOSTON, MA – January 28, 2026 – The U.S. Food and Drug Administration has cleared the path for what could be a paradigm shift in medicine, granting approval for the first-ever human clinical trial of a therapy designed to reverse cellular aging. Boston-based Life Biosciences announced today that its Investigational New Drug (IND) application for ER-100 is now cleared, allowing the company to begin testing its revolutionary treatment in patients with debilitating optic neuropathies.

The therapy, ER-100, represents a new frontier in biotechnology, employing a technique known as Partial Epigenetic Reprogramming (PER) to restore aged and damaged cells to a younger, healthier state. The initial Phase 1 trial will enroll patients suffering from open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION), two leading causes of irreversible vision loss for which current treatments are severely limited or non-existent.

The Science of Cellular Rejuvenation

At the heart of Life Biosciences' approach is the epigenome—a complex system of chemical markers that acts as a switchboard, telling our genes when to turn on and off. As we age, these epigenetic patterns can become disorganized, leading to cellular dysfunction and disease. ER-100 aims to reset this system without altering the underlying DNA sequence.

The therapy uses a controlled, localized dose of three of the four "Yamanaka factors"—transcription factors named after Nobel laureate Shinya Yamanaka, who discovered they could reprogram adult cells back into a pluripotent state similar to embryonic stem cells. Life Biosciences' approach, however, is deliberately partial. It uses a trio of factors known as OSK (OCT-4, SOX-2, and KLF-4) while pointedly excluding the fourth factor, c-Myc, which is associated with an increased risk of cancer.

This transient exposure to the OSK factors is designed to "wind back the clock" on cells, restoring youthful gene expression patterns and improving function. The goal is rejuvenation, not a complete reversion to an undifferentiated stem cell, thereby preserving the cell's identity and function—in this case, the crucial retinal ganglion cells of the eye.

“This important milestone in reaching the clinic is the result of years of research, optimization, and comprehensive nonhuman primate studies demonstrating controlled OSK expression, restoration of methylation patterns, and improved visual function, all of which has culminated in this IND clearance,” said Sharon Rosenzweig-Lipson, Ph.D., Chief Scientific Officer at Life Biosciences.

New Hope for Untreatable Blindness

The decision to first target optic neuropathies highlights a significant area of unmet medical need. These conditions are characterized by the death of retinal ganglion cells (RGCs), the neurons that form the optic nerve and connect the eye to the brain. Once these cells are lost, they do not naturally regenerate, resulting in permanent vision loss.

Open-angle glaucoma, a chronic neurodegenerative disease, is a leading cause of blindness worldwide. While often linked to high pressure inside the eye, nerve damage can continue even when pressure is controlled, and many patients suffer from the disease despite having normal eye pressure.

Even more dire is the prognosis for NAION, often called a "stroke of the eye." It causes sudden, painless vision loss in adults over fifty and has no approved treatments whatsoever. With an estimated 30,000 new cases in the U.S. each year, patients are left with few options beyond managing vascular risk factors to prevent an occurrence in their other eye. ER-100 offers the potential to be a first-in-class, disease-modifying therapy that could directly protect and potentially regenerate the damaged RGCs.

Navigating the Risks of a Cellular Rewind

Pioneering a field as transformative as cellular rejuvenation comes with significant challenges, chief among them being safety. The very power of Yamanaka factors to reprogram cells has historically raised concerns about the potential for uncontrolled cell growth and tumor formation.

Life Biosciences has implemented a multi-layered safety strategy to address these risks head-on. Beyond excluding the oncogenic c-Myc factor, ER-100 is designed for local, intravitreal injection directly into the eye. This approach dramatically limits systemic exposure and contains the therapy's effects to the target tissue.

Furthermore, the therapy incorporates a sophisticated "off-switch." The gene expression is controlled by a doxycycline-inducible system, meaning the therapeutic factors are only active in the presence of the common antibiotic. This gives clinicians precise control, allowing them to pause or halt the treatment if any adverse effects are observed. This careful design was crucial in securing the landmark IND clearance from the FDA and will be the primary focus of the Phase 1 safety and tolerability study.

The High-Stakes Race to Reverse Aging

Life Biosciences' achievement places it at the forefront of a burgeoning and highly competitive field focused on tackling aging itself as a treatable condition. The company, co-founded in 2017 by renowned Harvard longevity researcher Dr. David Sinclair, has raised over $150 million from investors keen to back this next wave of biotechnology.

While ER-100 is the first partial reprogramming therapy to enter the clinic, the race is heating up. Other companies are pursuing novel approaches for optic neuropathies, such as Oculis, which is developing a neuroprotective small molecule. The broader landscape includes advanced gene therapies and stem cell treatments also under investigation for their regenerative potential in the eye and nervous system. Even government agencies like ARPA-H are funding research into regenerating the optic nerve.

The successful IND clearance for ER-100, however, serves as a powerful validation of the epigenetic reprogramming approach. If the upcoming human trial can replicate the promising safety and efficacy results seen in preclinical primate studies, it would not only offer hope to millions facing blindness but also open the door to applying this platform technology to a vast array of other age-related diseases. The world of medicine will be watching closely as this first-of-its-kind trial gets underway.